Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.

Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antigens, CD19
Female
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Recurrence
Retrospective Studies
Treatment Outcome

authors with profiles

Peter Riedell
Michael Bishop